Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data
Authors:
- 22 March 2010
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (1) , 52-58
Abstract
Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for autologous transplant in patients with lymphoma and multiple myeloma. In this study, we present the first European compassionate use experience in mobilization failures, patients who are hardest to remobilize but were not included in registration trials. A total of 56 consecutive patients from 15 centers in Spain and the United Kingdom were included: age 60 (33–69) years; 29 men (32 with myeloma and 24 with lymphoma); 2 lines of previous chemotherapy (1–10); 73 previously failed mobilization attempts with G-CSF (28), chemotherapy plus G-CSF (43) or G-CSF plus SCF(2). Overall, 71% of patients reached 10 CD34+ cells per μL with plerixafor on day 5 after a 7.6-fold expansion from day 4. A total of 42 patients (75%) collected 2 × 106, average 3.0±1.7 (0.4–10.6) CD34+ cells per kg with plerixafor plus G-CSF. There were no severe drug-related adverse events. In all, 35 patients (63%) underwent transplant, receiving an average of 3.1±1.2 (1.9–7.7) × 106 CD34+ cells per kg. All patients engrafted neutrophils (day 12; 13.4±0.8; 8–30) and platelets (day 15; 18.5±2.4; 8–33). In our experience, plerixafor offers an effective alternative to collect sufficient CD34+ cells for autologous SCT from patients who fail conventional mobilization methods, with good tolerance and a high success rate.Keywords
This publication has 27 references indexed in Scilit:
- Trends of hematopoietic stem cell transplantation in the third millenniumCurrent Opinion in Hematology, 2009
- The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapiesBone Marrow Transplantation, 2009
- Chapter 2 CXCR4 and Mobilization of Hematopoietic Precursors2009
- Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous TransplantationTransplantation and Cellular Therapy, 2008
- Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignanciesBone Marrow Transplantation, 2007
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilizationBone Marrow Transplantation, 2002
- Autologous peripheral blood progenitor cell transplantation with <2×106 CD34+/kg: an analysis of variables concerning mobilisation and engraftmentThe Hematology Journal, 2000
- Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patientsThe Lancet, 1996
- Defining a Therapeutic Dose of Peripheral Blood Stem CellsJournal of Hematotherapy, 1992